Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (12) , e961-e985
Abstract
No abstract availableKeywords
Funding Information
- Multiple Myeloma Research Foundation
This publication has 19 references indexed in Scilit:
- Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/LymphomaBlood, 2019
- Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell LeukemiaClinical Lymphoma Myeloma and Leukemia, 2019
- Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2018
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2016
- Guidelines for determination of the number of prior lines of therapy in multiple myelomaBlood, 2015
- A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myelomaCancer, 2015
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- HyperCVAD for VAD-resistant multiple myelomaAmerican Journal of Hematology, 1996